MarkmanM.: Single-agent carboplatin is the treatment of choice in recurrent potentially platinum sensitive ovarian cancer.ASCO Educational book, 2002.
2.
GordonA., BookmanM., MalstromH.: Efficacy of TPT in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. Proc ASCO, 15: 73 (abst), 1996.
3.
GordonA., Ten Bokkel HuininkW., CarmichaelJ.: Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol (United States), 24(1 Suppl 5): S5–S25, 1997.
4.
HoskinsP., EisenhauerE., BeareS.: Randomized phase II of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Istitute of Canada Clinical Trials Group Study. J Clin Oncol, 16: 2014–2018, 1998.
5.
KudelkaA.P., TresukosolD., EdwardsC.L.: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol, 14: 1552–1557, 1996.
6.
Ten Bokkel HuininkW., GoreM., CarmichaelJ.: Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol, 15: 2183–2193, 1997.
7.
LambertH.E., RustinG.J., GregoryW.M.: A randomized trial of five vs eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol, 8: 327–333, 1997.
8.
HakesT.B., ChalasE., HoskinsW.J.: Randomized prospective trial of 5 vs 10 cycles of CAP in avanced ovarian carcinoma. Gynecol Oncol, 45: 284–289, 1992.
9.
DACOVA:A prospective randomized comparison of 6 and 12 cycles of CAP in advanced epithelial ovarian cancer. Gynecol Oncol, 49: 30–36, 1993.
10.
BerekJ.S., BertelsenK., du BoisA.: Advanced epithelial ovarian cancer: 1998 Consensus Statements. Ann Oncol, 10: S87–S92, 1999.
11.
BolisG., ScarfoneG., VillaA.: Phase I-II sequential TPT chemotherapy in PTS with small residual disease after TC as fist line chemotherapy in AEOC. Proc ASCO, 17: 1396 (abst), 1998.
12.
MCGuireW.P., BlessingJ.A., BookmanM.A.: Topotecan has substantial antitumor activity as first line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol, 18: 1062–1067, 2000.
13.
BolisG., ScarfoneG., SciattaC.: Phase I-II study of TPT in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol, 83: 477–480, 2001.
14.
BolisG., ScarfoneG., VillaA.: Phase II trial of TPC, carboplatin and paclitaxel as front line therapy in sub optimal advanced epithelial ovarian cancer. Gynecol Oncol, 82: 331–333, 2001.
15.
GiacconeG., DalesioO., McVieG.J.: Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol, 11: 1230–1240, 1993.
16.
ArdizzoniA., HansenH., DombernowskyP.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol, 15: 2090–2096, 1997.
17.
Von PawelJ., SchillerJ.H., ShepherdF.A.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 17: 658, 1999.
18.
SchutteW., ManegoldC., Von PawelJ.V.: Topotecan in the therapy of brain metastasis in lung cancer. Onkologie, 21(Suppl 4): 25–27, 1998.
19.
von PawelJ., GatzemeierU., PujolJ.L.: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol, 19: 1743–1749, 2001.
20.
ShepherdF.A.: Chemotherapy for advanced NSCLC: modest progress, many choices. J Clin Oncol, 18: 35–38, 2000.
21.
LynchT.J.Jr, KalishL., StraussG.: Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol, 12, 347–352, 1994.
22.
WeitzJ.J., MarschkeR.F.Jr., SloanJ.A.: A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer, 28: 157–162, 2000.
23.
Perez-SolerR., GlissonB.S., LeeJ.S.: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol, 14: 2785–2790, 1996.
24.
Perez-SolerR., FossellaF.V., GlissonB.S.: Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol, 14: 503–513, 1996.
25.
WhiteS.C., CheesemanS., ThatcherN.: Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res, 6: 868–873, 2000.
